Contents

Part 1: SPOTLIGHT-ROUTINE IMMUNIZATION AND VACCINES

1. **Bacillus Calmette-Guérin Vaccine** **3**
Suraj Gupte, Novy Gupte, Amisha Reddy, Shekhar Reddy
BCG Vaccine: A–Z *4*; BCG Vaccine: Indian Perspectives *6*

2. **Polio Vaccines** **11**
Suraj Gupte, Shefalli Koul, Novy Gupte
Polio Vaccines: A–Z Basics *12*; Polio Vaccines: Indian Perspectives *15*; Bidding Goodbye to Polio: Success Story *16*; Polio Eradication in India: Historical Landmarks *17*; Future Approach and Perspectives *17*

3. **Hepatitis B Vaccine** **22**
Novy Gupte, Suraj Gupte, Farida Dar, Shekhar Reddy
Hepatitis B Vaccine: A–Z *23*; Hepatitis B Vaccine: Recommendations in India *24*

4. **Diphtheria, Tetanus, and Pertussis Vaccines** **29**
Novy Gupte, Shefalli Koul, Suraj Gupte
DTP Vaccines: A–Z Basics *30*; DTP Vaccine: Indian Perspectives *31*

5. ***Haemophilus influenzae* Type B Conjugate Vaccine** **38**
Suraj Gupte, Novy Gupte, Farida Dar, Utpal Kant Singh
Hib Vaccine: A–Z *39*; Hib Vaccine: Indian Perspectives *40*

6. **Pneumococcal Vaccines** **44**
Novy Gupte, Suraj Gupte, Sanjeev Mehta
Pneumococcal Vaccines: A–Z *45*; Pneumococcal Vaccines: Recommendations in India *46*

7. **Rotavirus Vaccine** **54**
Suraj Gupte, Novy Gupte, Utpal Kant Singh
Rotavirus Vaccines: A–Z Basics *55*; Rotavirus Vaccine: Indian Perspectives *56*

8. Measles Vaccine **63**
Novy Gupte, Suraj Gupte, Sanjeev Mehta, Utpal Kant Singh
Measles Vaccine *64*; Measles Vaccine: Indian Perspectives *65*

9. Measles, Mumps, and Rubella Vaccine **71**
Novy Gupte, Suraj Gupte, Shefalli Koul
MMR Vaccine: A–Z *73*; MMR Vaccine: Indian Perspectives *73*

10. Varicella Vaccine **78**
Novy Gupte, Suraj Gupte, Amisha Reddy, Shekhar Reddy
Varicella Vaccines: A–Z *79*; Varicella Vaccine: Indian Perspectives *80*

11. Hepatitis A Vaccines **90**
Suraj Gupte, Novy Gupte, Utpal Kant Singh
Hepatitis A Vaccines: A–Z *91*; Hepatitis A Vaccine: Indian Perspectives *93*

12. Typhoid Vaccines **97**
Suraj Gupte, Novy Gupte, Amisha Reddy
Typhoid Vaccines: A–Z *98*; Typhoid Vaccines: Indian Perspectives *101*

13. Human Papillomavirus Vaccines **105**
Suraj Gupte, Novy Gupte, Utpal Kant Singh
HPV Vaccines: A–Z *106*; HPV Vaccines: Indian Perspectives *108*

Part 2: FEVER SPECTRUM

14. Fever of Unknown Origin **115**
Ajay Kalra
Etiological Considerations *116*; Evaluation *122*; Treatment *126*; Prognosis *126*

15. Fever with Rash **129**
Pratibha Kale, Satish K Tiwari
Etiology *129*; Approach to the Case of Fever with Rash *130*; Differential Diagnosis *136*; Investigation *136*; Treatment *139*; Prevention *141*; Prognosis *142*

16. Fever without Focus **144**
Sara Dhanawade

Relevant Definitions *145*; Etiologic Agents *145*; Epidemiology *145*; Approach to the Young Febrile Child *146*; Indian Scenario *152*

Part 3: PARASITIC INFECTIOUS DISEASES

17. Pediatric Kala-Azar **159**
Prakash Narain Nigam

Etiology *159*; Epidemiology *160*; Modes of Transmission *160*; Pathogenesis *161*; Clinical Features *161*; Laboratory Diagnosis *162*; Direct Evidences *162*; Immunodiagnosis *163*; Molecular Methods *164*; Indirect Evidences (Nonleishmanian Tests) *165*; Treatment *165*; Supportive Care *166*; Response to Treatment *167*; Visceral Leishmaniasis in HIV Coinfected Patients *167*; Prevention and Control *167*; Leishmania Scope of Vaccine *168*

18. Malaria: Current Diagnosis and Therapeutics **171**
Ravinder K Gupta, Ritu Gupta, Asma Saheen

Prevalence *172*; Diagnosis of Malaria *173*; Aims and Objectives of Treatment of Malaria *177*; Antimalarial Drugs *178*; Treatment of Uncomplicated Malaria *189*; Severe and Complicated Falciparum Malaria *191*; Supportive Therapy *194*; Prevention and Control *197*; National Drug Policy on Malaria (2013) *201*; Drug Schedule for Treatment of Malaria Under NVBDCP *207*

Part 4: FUNGAL INFECTIONS

19. Fungal Infections in Critically Ill Chidren **217**
BP Karunakara, MV Prashanth, R Nidhi

Epidemiology *218*; Risk Factors for Fungal Infections *218*; Candidiasis *219*; *Aspergillus* Species Infection *225*; Mucorales *227*; Cryptococcosis *228*; Histoplasmosis *229*; Antifungal Medications *229*

Part 5: NEONATAL INFECTIONS

20. Neonatal Sepsis: Newer Diagnostic Markers **237**
Rahul Bhamkar, Anjali Kulkarni

Physiological Markers *238*; Hematological Markers *238*; Microbiological Methods *239*; Acute Phase Reactants *240*; Cell Surface Markers *241*; Molecular Diagnostics *242*

21. Perinatal Listeriosis **249**
Bahubali D Gane, B Vishnu Bhat
Bacteriology *250*; Epidemiology *250*; Pathogenesis *251*; Clinical Manifestations *251*; Diagnosis *253*; Management *253*; Prognosis *254*; Prevention *255*

Part 6: THERAPEUTICS

22. Pharmacotherapy of Helminthic Diseases **261**
Novy Gupte, Suraj Gupte
Nematodes (Roundworms) *262;* Trematodes (Flukes) *268*; Cestodes (Tapeworms) *268*; Currently Employed Key Anthelmintics: Salient Pharmacologic Features *271*

23. Antifungal Medications in Pediatric Practice **280**
Novy Gupte
Classification *281*; Polyens *281*; Azoles *282*; Allylamine *284*; Miscellaneous Antifungals *284*

Part 7: MISCELLANEOUS ISSUES

24. Recurrent Respiratory Tract Infections **289**
Dhaarani Jayaraman, Pankaj C Vaidya, Satish K Tiwari
Pathophysiology *291*; Risk Factors *292*; Microbiological Profile *293*; Clinical Approach *294*; Investigations *297*; Management *299*; Future Treatment Options *300*; Prognosis *300*

25. Cough in Infants, Children and Adolescents **304**
Suraj Gupte, Rita Forfar, ME William
Modus Operandi of Production *305*; Classifications *305*; Etiologic Considerations *306*; Fact Sheet of Important Causes of Cough *306*; Evaluation and Diagnostic Approach *312*; Differential Diagnosis *315*; Complications *315*; Management *315*; Algorithmic Approach *319*

26. Vaccine Preventable Central Nervous System Infections **323**
Sheffali Gulati, Biswaroop Chakrabarty
Bacterial Infections *323*; Viral Infections *335*; Impact of Vaccination *339*

27. Urinary Tract Infection **347**
PK Pruthi
Epidemiology *348*; Etiopathogenesis *348*; Risk Factors for UTI *348*; Clinical Features *349*; Lower Versus Upper UTI *350*; Physical Examination *350*; Diagnosis *350*; Management *354*; Vesicoureteric Reflux *357;* Antibiotic Prophylaxis *361*; Risk Factors for Renal Scarring *362*; Complications of UTI *363*

28. Revisiting Viral Hepatitis **370**
ES Sherlock, Suraj Gupte
Hepatitis A *371*; Hepatitis B *376*; Hepatitis D *392*; Hepatitis E *394*; Hepatitis F *397*; Hepatitis G *397*

Index *401*